NW Bio To Present At The 2nd Immunotherapy Of Cancer Conference, ITOC-2
BETHESDA, MD, March 24, 2015 – Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, Chief Technical Officer, will present at the 2nd Immunotherapy of Cancer Conference, ITOC-2, being held in Munich, Germany from March 25-27, 2015.
The Company’s presentation will take place on Thursday, March 26 at 2:40 p.m. local time (9:40 a.m. EDT) in Auditorium A at Hörsaal A, Klinikum rechts der Isar, TU Munich, Ismaniger Str. 22. There will be a live audio webcast of the 15 minute presentation available at https://nwbio.com/webcasts/.
During his presentation, Dr. Bosch will discuss data relating to 51 patients with Glioblastoma multiforme (GBM) brain cancer who were treated with DCVax-L on a compassionate basis in an “Information Arm” outside of the Company’s Phase III clinical trial. These patients were not eligible for the clinical trial because they were already showing some actual or apparent re-growth of their brain tumor in imaging at a Baseline Visit when they finished 6 weeks of daily radiotherapy and chemotherapy following the surgical removal of their original tumor as part of the standard of care. Such patients are considered either “rapid progressors” or “pseudo-progressors,” based upon whether the appearance of early tumor re-growth can be subsequently confirmed. Dr. Bosch will discuss survival data relating to such patients.
The ITOC conference will focus on topics such as immunomodulatory agents, anti-cancer vaccines, adoptive and engineered T cell Therapy and monoclonal antibodies.
The Society for Immunotherapy of Cancer is partnering with The Cancer Drug Development Forum for this conference.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead program is a 348-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is under way with a 60-patient Phase I/II trial with DCVax-Direct for all inoperable solid tumors cancers, with a primary efficacy endpoint of tumor regression. It has completed enrollment in the Phase I portion of the trial. The Company previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer. The Company conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania. In Germany, the Company has received approval of a 5-year Hospital Exemption for the treatment of all gliomas (brain cancer) patients outside the clinical trial.
Disclaimer
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ongoing ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s and Cognate’s abilities to carry out the intended manufacturing expansions contemplated in the Cognate Agreements, risks related to the Company’s ability to carry out the Hospital Exemption program and risks related to possible reimbursement and pricing. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
CONTACTS:
Les Goldman
202-841-7909
Farrell Kramer (Media)
212-710-9685
Jane Searle (Investors)
212-710-9686
